share_log

Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)

Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)

Ensysce Biosciences宣佈,該公司可能會繼續在納斯達克資本市場層面上市,並將延期至2024年5月13日,以證明其遵守了上市規則5550 (b) (1) 中的股權要求
Benzinga ·  02/27 08:11

Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq"), as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to May 13, 2024 in order to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1).

應用變革性化學提高處方藥安全性的臨床階段公司Ensysce Biosciences, Inc.(“公司”)(納斯達克股票代碼:ENSC)今天宣佈,它已收到納斯達克股票市場有限責任公司(“納斯達克”)的通知,如2024年2月26日的決定所述,該公司可能會繼續在納斯達克資本市場層面上市,並將延期至2024年5月13日,以證明合規性符合《上市規則》第5550 (b) (1) 條的股權要求。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論